Initiation and resolution of mucosal inflammation

Immunologic Research

Volumn 29, Issue 1-3, 2004, Pages 241-252

  Sherman, Melanie A ^a,b   Kalman, Daniel ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Citrobacter rodentium; Enteric pathogen; Hyperplasia; Inflammatory bowel disease; Interleukin 10; Mucosal immunity; Regulatory T cell

Indexed keywords

CANCER GROWTH FACTOR; GAMMA INTERFERON; GLUCOCORTICOID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

BACTERIAL INFECTION; CITROBACTER; CITROBACTER RODENTIUM; CLINICAL FEATURE; COLITIS; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENTERITIS; ESCHERICHIA COLI; HYPERPLASIA; IMMUNE RESPONSE; INFECTION SENSITIVITY; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; BACTERIAL INFECTIONS; CITROBACTER RODENTIUM; ENTEROBACTERIACEAE INFECTIONS; ENTEROCOLITIS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MICE; T-LYMPHOCYTES;

EID: 3042560117     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:29:1-3:241     Document Type: Review

References (77)

1. Mowat AM: Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003;3:331-341.
2. Sadlack B, Merz, H, Schorle, H, et al.: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-261.
3. Kuhn R, Lohler, J, Rennick, D, et al.: Interleukin-10 deficient mice develop chronic enterocholitis. Cell 1993;75:263-274.
4. Mombaerts P, Mizoguchi, E, Grusby, MJ, et al.: Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75: 274-282.
5. Fiorucci S, Mencarelli, A, Palazzetti, B, et al.: Importance of innate immunity and collagen binding integrin alphalbetal in TNBS-induced colitis. Immunity 2002; 17:769-780.
6. Ogura Y, Bonen, DK, Inohara, N, et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606.
7. Strober W, Nakamura, K, and Kitani, A: The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease. J Clin Invest 2001;107:667-670.
8. Taurog JD, Richardson, JA, Croft, JT, et al.: The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-2364.
9. Dianda L, Hanby, AM, Wright, NA, et al.: T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997;150:91-97.
10. Wei B, Huang, T, Dalwadi, H, et al.: Pseudomonas fluorescens encodes the Crohn's disease-associated 12 sequence and T-cell superantigen. Infect Immun 2002;70:6567-6575.
11. Dalwadi H, Wei, B, Kronenberg, M, et al.: The Crohn's disease-associated bacterial protein 12 is a novel enteric T cell superantigen. Immunity 2001;15:149-158.
12. Boudeau J, Glasser, AL, Masseret, E, et al.: Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun 1999;67:4499-4509.
13. Glasser AL, Boudeau, J, Barnich, N, et al.: Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001;69:5529-5537.
14. Kallinowski F, Wassmer, A, Hofmann, MA, et al.: Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Hepatogastroenterology 1998;45:1552-1558.
15. Neut C, Bulois, P, Desreumaux, P, et al.: Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002;97:939-946.
16. Neutra MR, Pringault, E and Kraehenbuhl, JP: Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol 1996;14:275-300.
17. Rescigno M, Urbano, M, Valzasina, B, et al.: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001;2:361-367.
18. Sabroe I, Parker, LC, Wilson, AG, et al.: Toll-like receptors: their role in allergy and non-allergic inflammatory disease. Clin Exp Allergy 2002;32:984-989.
19. Abreu MT, Vora, P, Faure, E, et al.: Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167:1609-1616.
20. Abreu MT, Arnold, ET, Thomas, LS, et al.: TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002;277:20431-20437.
21. Gewirtz AT, Navas, TA, Lyons, S, et al.: Cutting edge: bacterial flagellin activates basolaterally expressed tlr5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167:1882-1885.
22. Ortega-Cava CF, Ishihara, S, Rumi, MA, et al.: Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003;170:3977-3985.
23. House D, Bishop, A, Parry, C, et al.: Typhoid fever: pathogenesis and disease. Curr Opin Infect Dis 2001;14:573-578.
24. Wershil BK, Castagliuolo, I and Pothoulakis, C: Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology 1998;114:956-964.
25. Su B, Ceponis, PJ, Lebel, S, et al.: Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun 2003;71: 3496-3502.
26. Crabtree JE: Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage. Dig Dis Sci 1998;43:46S-55S.
27. Gionchetti P, Vaira, D, Campieri, M, et al.: Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol 1994;89: 883-887.
28. Nataro JP and Kaper JB: Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142-201.
29. Celli J, Olivier, M, and Finlay, BB: Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways. EMBO J 2001;20:1245-1258.
30. Stein MA, Mathers, DA, Yan, H, et al.: Enteropathogenic Escherichia coli markedly decreases the resting membrane potential of Caco-2 and HeLa human epithelial cells. Infect Immun 1996;64:4820-4825.
31. Powrie F, Correa-Oliveira, R, Mauze, S, et al.: Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589-600.
32. Powrie F, Leach, MW, Mauze, S, et al.: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-1471.
33. Pontoux C, Banz, A and Papiernik, M: Natural CD4 CD25(+) regulatory T cells control the burst of super-antigen-induced cytokine production: the role of IL-10. Int Immunol 2002;14:233-239.
34. Sakaguchi S, Sakaguchi, N, Asano, M, et al.: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Break-down of a single mechanism of self- tolerance causes various autoimmune diseases. J Immunol 1995;155: 1151-1164.
35. Wolf M, Schimpl, A and Hunig, T: Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur J Immunol 2001;31:1637-1645.
36. Thornton AM and Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
37. Asano M, Toda, M, Sakaguchi, N, et al.: Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-396.
38. Itoh M, Takahashi, T, Sakaguchi, N, et al.: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999;162:5317-5326.
39. Graca L, Thompson, S, Lin, CY, et al.: Both CD4(+) CD25(+) and CD4(+) CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002;168: 5558-5565.
40. Lehmann J, Huehn, J, de la Rosa, M, et al.: Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci USA 2002;99:13031-13036.
41. Uraushihara K, Kanai, T, Ko, K, et al.: Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells. J Immunol 2003;171:708-716.
42. Auernhammer CJ, Bousquet, C and Melmed, S: Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci USA 1999;96:6964-6969.
43. Suzuki A, Hanada, T, Mitsuyama, K, et al.: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001;193:471-481.
44. Fiorentino DF, Zlotnik, A, Mosmann, TR, et al.: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822.
45. D'Andrea A, Aste-Amezaga, M, Valiante, NM, et al.: Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048.
46. Gruber MF, Williams, CC and Gerrard, TL: Macrophage-colony-stimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 beta and inhibited by IL-4 and IL-10. J Immunol 1994;152:1354-1361.
47. Berkman N, John, M, Roesems, G, et al.: Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. J Immunol 1995;155:4412-4418.
48. Marfaing-Koka A, Maravic, M, Humbert, M, et al.: Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. Int Immunol 1996;8:1587-1594.
49. Kopydlowski KM, Salkowski, CA, Cody, MJ, et al.: Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol 1999;163:1537-1544.
50. Muzio M, Bosisio, D, Polentarutti, N, et al.: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000;164:5998-6004.
51. Moore KW, de Waal Malefyt, R, Coffman, RL, et al.: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
52. Lindsay JO, Ciesielski, CJ, Scheinin, T, et al.: Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 2003;52:363-369.
53. Braat H, Peppelenbosch, MP and Hommes, DW: Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin Biol Ther 2003;3:725-731.
54. Donnenberg MS: Enteropathogenic Escherichia coli. In Infections of the Gastrointestinal Tract. Blaser M, Smith P, Rardin J, et al. (eds.) Lippincott Williams & Wilkins, Philadelphia, 2002, pp. 595-612.
55. Mead PS, Slutsker, L, Dietz, V, et al.: Food-related illness and death in the United States. Emerg Infect Dis 1999;5:607-625.
56. Goffaux F, China, B, Janssen, L, et al.: Genotypic characterization of enteropathogenic Escherichia coli (EPEC) isolated in Belgium from dogs and cats. Res Microbiol 2000;151:865-871.
57. Marches O, Nougayrede, JP, Boullier, S, et al.: Role of tir and intimin in the virulence of rabbit enteropathogenic Escherichia coli serotype 0103:H2. Infect Immun 2000;68:2171-2182.
58. Oswald E, Schmidt, H, Morabito, S, et al.: Typing of intimin genes in human and animal enterohemorrhagic and enteropathogenic Escherichia coli: characterization of a new intimin variant. Infect Immun 2000;68:64-71.
59. McDaniel TK, Jarvis, KG, Donnenberg, MS, et al.: A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci USA 1995;92:1664-1668.
60. McDaniel TK and Kaper JB: A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol Microbiol 1997;23:399-407.
61. Newman JV, Zabel, BA, Jha, SS, et al.: Citrobacter rodentium espB is necessary for signal transduction and for infection of laboratory mice. Infect Immun 1999;67:6019-6025.
62. Klapproth JM, Donnenberg, MS, Abraham, JM, et al.: Products of enteropathogenic Escherichia coli inhibit lymphocyte activation and lymphokine production. Infect Immun 1995;63:2248-2254.
63. Klapproth JM, Scaletsky, IC, McNamara, BP, et al.: A large toxin from pathogenic Escherichia coli strains that inhibits lymphocyte activation. Infect Immun 2000;68:2148-2155.
64. Vallance BA, Deng, W, Jacobson, K, et al.: Host susceptibility to the attaching and effacing bacterial pathogen Citrobacter rodentium. Infect Immun 2003; 71:3443-3453.
65. Higgins LM, Frankel, G, Connerton, I, et al.: Role of bacterial intimin in colonic hyperplasia and inflammation. Science 1999;285:588-591.
66. Higgins LM, Frankel, G, Douce, G, et al.: Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun 1999;67: 3031-3039.
67. Frankel G, Lider, O, Hershkoviz, R, et al.: The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta1 integrins. J. Biol. Chem. 1996;271:20359-20364.
68. Umar S, Scott, J, Sellin, JH, et al.: Murine colonic mucosa hyperproliferation. I. Elevated CFTR expression and enhanced cAMP-dependent CI(-) secretion. Am J Physiol Gastrointest Liver Physiol 2000;278: G753-G764.
69. Salvati VM, Bajaj-Elliott, M, Poulsom, R, et al.: Keratinocyte growth factor and coeliac disease. Gut 2001;49:176-181.
70. Bajaj-Elliott M, Poulsom, R, Pender, SL, et al.: Interactions between stromal cell-derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia. J Clin Invest 1998;102:1473-1480.
71. Savkovic SD, Koutsouris, A and Hecht, G: Attachment of a noninvasive enteric pathogen, enteropathogenic Escherichia coli, to cultured human intestinal epithelial monolayers induces transmigration of neutrophils. Infect Immun 1996;64:4480-4487.
72. Vallance BA, Deng, W, Knodler, LA, et al.: Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection. Infect Immun 2002;70:2070-2081.
73. Simmons CP, Goncalves, NS, Ghaem-Maghami, M, et al.: Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-gamma. J Immunol 2002;168: 1804-1812.
74. Vallance BA, Deng, W, De Grado, M, et al.: Modulation of inducible nitric oxide synthase expression by the attaching and effacing bacterial pathogen citrobacter rodentium in infected mice. Infect Immun 2002;70: 6424-6435.
75. Luperchio SA and Schauer DB: Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonie hyperplasia. Microbes Infect 2001;3:333-340.
76. Smith JA and Bluestone JA: T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol 1997;9:648-654.
77. Merger M, Viney, JL, Borojevic, R, et al.: Defining the roles of perform, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut 2002;51:155-163.